These results demonstrate that the discovered mtDNA mutation is associated to mitochondrial dysfunction in PARK2-PD fibroblasts, and suggest that there is no compensatory activation of mitochondrial biogenesis as TFAM and other PGC-1α downstream target genes are downregulated or unchanged [39]. The gene discussed is PPARGC1A; the disease is Parkinson disease.